Barker Juliet N, Wagner John E
Department of Medicine, Blood and Marrow Transplant Program of the University of Minnesota School of Medicine, 420 Delaware Street, S.E., Minneapolis, Minnesota 55455, USA.
Nat Rev Cancer. 2003 Jul;3(7):526-32. doi: 10.1038/nrc1125.
Haematopoietic stem-cell transplantation is used to treat many haematological cancers, but is limited by the lack of suitable bone-marrow donors, the risk of graft-versus-host disease (GVHD) and slow immune reconstitution. Umbilical-cord blood is an alternative source of haematopoietic stem cells that has recently been tested in both child and adult cancer patients. These studies have identified several advantages to umbilical-cord cell transplantation, including a lower incidence of GVHD. Umbilical-cord blood is therefore a promising alternative to bone-marrow-derived stem cells.
造血干细胞移植用于治疗多种血液系统癌症，但受到缺乏合适骨髓供体、移植物抗宿主病（GVHD）风险以及免疫重建缓慢的限制。脐带血是造血干细胞的另一种来源，最近已在儿童和成人癌症患者中进行了测试。这些研究已经确定了脐带血细胞移植的几个优点，包括GVHD发病率较低。因此，脐带血是骨髓来源干细胞的一种有前途的替代物。
